Sercan Aksoy

10.3k total citations · 2 hit papers
284 papers, 3.6k citations indexed

About

Sercan Aksoy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sercan Aksoy has authored 284 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Oncology, 91 papers in Pulmonary and Respiratory Medicine and 51 papers in Cancer Research. Recurrent topics in Sercan Aksoy's work include HER2/EGFR in Cancer Research (41 papers), Cancer Treatment and Pharmacology (40 papers) and Breast Cancer Treatment Studies (37 papers). Sercan Aksoy is often cited by papers focused on HER2/EGFR in Cancer Research (41 papers), Cancer Treatment and Pharmacology (40 papers) and Breast Cancer Treatment Studies (37 papers). Sercan Aksoy collaborates with scholars based in Türkiye, United States and India. Sercan Aksoy's co-authors include Kadri Altundağ, Saadettin Kılıçkap, Deniz Can Güven, Mehmet Alı Nahıt Şendur, Ömer Dızdar, Taha Koray Şahin, Hakan Harputluoğlu, İbrahim Barışta, Nurullah Zengin and Enes Erul and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sercan Aksoy

254 papers receiving 3.5k citations

Hit Papers

The association between a... 2022 2026 2023 2024 2022 2024 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    2022 138 citations Deniz Can Güven, Taha Koray Şahin et al. profile →
  2. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis
    2024 111 citations Taha Koray Şahin, Sercan Aksoy et al. Cancers profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sercan Aksoy 1.7k 780 554 430 428 284 3.6k
Stefania Gori 2.0k 1.2× 897 1.1× 680 1.2× 694 1.6× 281 0.7× 180 3.5k
Saverio Cinieri 2.5k 1.4× 930 1.2× 1.0k 1.8× 957 2.2× 230 0.5× 206 4.3k
Ephraim P. Hochberg 1.9k 1.1× 410 0.5× 619 1.1× 248 0.6× 283 0.7× 148 5.2k
Aarón Sulkes 1.8k 1.0× 984 1.3× 465 0.8× 308 0.7× 627 1.5× 164 3.3k
J. Michael Straughn 1.3k 0.7× 467 0.6× 1.0k 1.8× 452 1.1× 795 1.9× 192 4.4k
David J. Straus 2.9k 1.7× 1.2k 1.6× 604 1.1× 235 0.5× 356 0.8× 175 6.5k
Michael Schaapveld 2.2k 1.2× 1.2k 1.6× 444 0.8× 1.1k 2.5× 1.2k 2.9× 155 5.7k
Erik Jakobsen 2.3k 1.3× 1.6k 2.0× 657 1.2× 1.1k 2.6× 462 1.1× 151 4.3k
Flora Zagouri 1.7k 1.0× 718 0.9× 1.2k 2.1× 873 2.0× 491 1.1× 301 4.0k
Séamus O’Reilly 3.9k 2.2× 1.2k 1.6× 1.4k 2.5× 756 1.8× 967 2.3× 227 6.8k

Countries citing papers authored by Sercan Aksoy

Since Specialization
Citations

This map shows the geographic impact of Sercan Aksoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sercan Aksoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sercan Aksoy more than expected).

Fields of papers citing papers by Sercan Aksoy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sercan Aksoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sercan Aksoy. The network helps show where Sercan Aksoy may publish in the future.

Co-authorship network of co-authors of Sercan Aksoy

This figure shows the co-authorship network connecting the top 25 collaborators of Sercan Aksoy. A scholar is included among the top collaborators of Sercan Aksoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sercan Aksoy. Sercan Aksoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yıldırım, Hasan Çağrı, et al.. (2025). Breast Radiotherapy: A Potential Risk Factor for Resistant Clone Development in Patients with Brain Metastasis. SHILAP Revista de lepidopterología. 11(1). 7–13. 1 indexed citations
2.
3.
Güven, Deniz Can, Necla Özer, Yusuf Ziya Şener, et al.. (2025). Serum Albumin–Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer. Journal of Clinical Medicine. 14(5). 1741–1741. 2 indexed citations
4.
5.
Özçakar, Levent, Mehmet Ruhi Onur, Oktay Halit Aktepe, et al.. (2024). Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy. Cancers. 16(5). 1061–1061. 1 indexed citations
6.
Cho, Byoung Chul, Irene Braña, Beatriz Cirauqui, et al.. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer. 23(S1). 1254–1254. 5 indexed citations
7.
Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations
8.
Ozcelikay, Göksu, Emirhan Nemutlu, Síbel A. Özkan, et al.. (2023). Molecularly imprinted electrochemical sensor for the selective and sensitive determination of octreotide in cancer patient plasma sample. Talanta. 263. 124679–124679. 7 indexed citations
9.
Aksoy, Sercan, Burcu Çakar, Gül Başaran, et al.. (2023). Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group. Cancers. 15(6). 1667–1667. 1 indexed citations
10.
Saatci, Özge, Özge Akbulut, Metin Çetįn, et al.. (2023). Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. Cell Death and Differentiation. 30(5). 1305–1319. 21 indexed citations
11.
Saatci, Özge, Metin Çetįn, Ünal Metin Tokat, et al.. (2023). Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer. Nature Communications. 14(1). 6997–6997. 6 indexed citations
12.
13.
Yıldırım, Hasan Çağrı, Deniz Can Güven, Oktay Halit Aktepe, et al.. (2022). Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. Journal of Clinical Medicine. 11(17). 5171–5171. 5 indexed citations
14.
Güven, Deniz Can, Taha Koray Şahin, Enes Erul, et al.. (2022). The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. Journal of Clinical Medicine. 11(15). 4523–4523. 22 indexed citations
15.
Nemutlu, Emirhan, Tuba Reçber, Cemil Can Eylem, et al.. (2022). Liquid biopsy markers for early diagnosis of brain metastasis patients with breast cancer by metabolomics. European Journal of Mass Spectrometry. 28(1-2). 56–64. 9 indexed citations
16.
Ünlütürk, Uğur, et al.. (2021). Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review. Immunotherapy. 13(14). 1157–1163. 5 indexed citations
17.
İnkaya, Ahmet Çağkan, Sercan Aksoy, Osman Abbasoğlu, et al.. (2021). Investigation of Intestinal Protozoon Prevalence in Immunocompromised Patients at a University Hospital. SHILAP Revista de lepidopterología. 45(1). 39–44. 9 indexed citations
18.
Onur, R., Deniz Can Güven, Salih Aksu, et al.. (2020). 1504O Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer. Annals of Oncology. 31. S932–S932.
19.
İnkaya, Ahmet Çağkan, et al.. (2019). The investigation of <i>Strongyloides stercoralis</i> seroprevalence in immunosupressed patients in Turkey. TURKISH JOURNAL OF MEDICAL SCIENCES. 49(1). 16–19. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefania Gori Breakdown of academic impact, for papers by Saverio Cinieri Breakdown of academic impact, for papers by Ephraim P. Hochberg Breakdown of academic impact, for papers by Aarón Sulkes Breakdown of academic impact, for papers by J. Michael Straughn Breakdown of academic impact, for papers by David J. Straus Breakdown of academic impact, for papers by Michael Schaapveld Breakdown of academic impact, for papers by Erik Jakobsen Breakdown of academic impact, for papers by Flora Zagouri Breakdown of academic impact, for papers by Séamus O’Reilly
Rankless by CCL
2026